Slow-moving regulators have kept the rules of engagement on social media platforms fuzzy for pharma players. Yet rather than sit on the sidelines waiting for the FDA to take a firm stance on dos and don’ts, many pharma companies have taken a shot at safe moves in the social realm.

Source: www.fiercebiotechit.com